JPS62195320A - Composition for oral cavity - Google Patents
Composition for oral cavityInfo
- Publication number
- JPS62195320A JPS62195320A JP3623186A JP3623186A JPS62195320A JP S62195320 A JPS62195320 A JP S62195320A JP 3623186 A JP3623186 A JP 3623186A JP 3623186 A JP3623186 A JP 3623186A JP S62195320 A JPS62195320 A JP S62195320A
- Authority
- JP
- Japan
- Prior art keywords
- dextranase
- salt
- composition
- sodium
- sarcosine salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 210000000214 mouth Anatomy 0.000 title abstract description 3
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical class CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical group CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 208000002064 Dental Plaque Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 5
- 108010001682 Dextranase Proteins 0.000 abstract description 27
- 230000002195 synergetic effect Effects 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 6
- 208000002925 dental caries Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 208000010266 Aggressive Periodontitis Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 201000006727 periodontosis Diseases 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 230000007505 plaque formation Effects 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000000606 toothpaste Substances 0.000 description 8
- 229940034610 toothpaste Drugs 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical class CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 208000028169 periodontal disease Diseases 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 4
- 241000194019 Streptococcus mutans Species 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 229940085605 saccharin sodium Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- -1 alcohol sulfate esters Chemical class 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 2
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-M 6-aminohexanoate Chemical compound NCCCCCC([O-])=O SLXKOJJOQWFEFD-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- XCOJIVIDDFTHGB-UEUZTHOGSA-N Perillartine Chemical compound CC(=C)[C@H]1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-UEUZTHOGSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910002026 crystalline silica Inorganic materials 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-UHFFFAOYSA-N para-methoxycinnamaldehyde Natural products COC1=CC=C(C=CC=O)C=C1 AXCXHFKZHDEKTP-UHFFFAOYSA-N 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AUHKUMFBHOJIMU-UHFFFAOYSA-M sodium;2-[hexadecanoyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCCCCC(=O)N(C)CC([O-])=O AUHKUMFBHOJIMU-UHFFFAOYSA-M 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
産業上の利
本発明は、歯垢形成抑制効果が高く、う触や歯周病の予
防効果に優れた口腔用組成物に関する。DETAILED DESCRIPTION OF THE INVENTION Industrial Advantages The present invention relates to an oral composition that is highly effective in inhibiting dental plaque formation and excellent in preventing caries and periodontal disease.
２来の ′１ び ■がタ しようとする５、ｒ′占歯
垢は、デキストラン等の細菌による代ａ１産物、細菌群
、唾液成分、食物残液などが歯牙に沈着したもので、歯
垢中の口腔細菌により生成される有機酸やある種のプロ
テアーゼ類かう触や歯周病の主要原因の１つとされてい
る。即ち、歯垢はう触や歯周病の原因菌に活動の場を提
供すると共に。5. Dental plaque is the accumulation of bacterial products such as dextran, bacterial groups, saliva components, food residue, etc., deposited on the teeth. Organic acids and certain proteases produced by oral bacteria are considered to be one of the main causes of tooth decay and periodontal disease. In other words, plaque provides a place for the bacteria that cause cavities and periodontal disease to play.
これら細菌により産生された酸や組織破壊をもたらす酵
素類を長時間滞留せしめる場ともなっている。It also serves as a place where acids produced by these bacteria and enzymes that cause tissue destruction remain for long periods of time.
従って、う触や歯周病の予防と治療のためには、歯垢の
形成抑制或いは分解除去を行なうことが有効であり、こ
のため従来よりこの点に関する研究が数多くなされてい
る。Therefore, in order to prevent and treat dental caries and periodontal disease, it is effective to suppress the formation of dental plaque or decompose and remove it, and for this reason, many studies have been conducted in this regard.
歯垢形成には、ショ糖を基質としてストレプトコッカス
・ミュータンスにより生成されるデキストラン等のグル
カンが重要な役割を果たすことが知られているが、この
ようなストレプトコッカス・ミュータンスによる歯垢の
形成を抑制するために従来口腔用組成物に殺菌剤を配合
することが行なわれている。しかし、殺菌剤を高濃度で
配合することは、安全性の点で好ましくない。It is known that glucan such as dextran produced by Streptococcus mutans using sucrose as a substrate plays an important role in plaque formation. In order to suppress this, a bactericidal agent has been conventionally incorporated into oral compositions. However, from the viewpoint of safety, it is not preferable to incorporate a disinfectant at a high concentration.
また、ストレプトコッカス・ミュータンスによる歯垢の
形成を抑制する有効成分としてデキストラナーゼが公知
であるが、デキストラナーゼは口腔用組成物に対する配
合量に限界がある。Furthermore, dextranase is known as an active ingredient that suppresses the formation of dental plaque due to Streptococcus mutans, but there is a limit to the amount of dextranase that can be added to oral compositions.
このため、従来より歯垢形成抑制効果のより高い口腔用
組成物が望まれていた。For this reason, there has been a desire for an oral cavity composition that is more effective in inhibiting dental plaque formation.
本発明は、上記事情に鑑みなされたもので、優れた歯垢
形成抑制効果を有し、しかも使用上の安全性も高い口腔
用組成物を提供することを目的とする。The present invention was made in view of the above circumstances, and an object of the present invention is to provide an oral composition that has an excellent effect of inhibiting plaque formation and is also highly safe in use.
ｎ・ 占 するための び・
即ち、本発明者らは、歯垢の抑制１分解除去に優れた有
効成分につき鋭意研究を重ねた結果、従来起泡性や洗浄
力を高めるための界面活性剤として知られたＮ−パルミ
トイルザルコシン塩やＮ −ミリストイルザルコシン塩
をデキストラナーゼと併用した場合、これらが相乗的に
作用し、顕著な歯垢抑制効果を発揮することを知見し、
本発明をなすに至ったものである。In other words, the present inventors have conducted extensive research into active ingredients that are excellent in suppressing and decomposing plaque, and have discovered that conventional surfactants for increasing foaming properties and cleaning power have been found. We found that when N-palmitoyl sarcosine salt and N-myristoyl sarcosine salt, known as dextranase, are used in combination with dextranase, they act synergistically and exert a remarkable plaque-inhibiting effect.
This is what led to the present invention.
なお、従来、Ｎ−ラウロイルザルコシン塩を含むＮ−長
鎖アシルアミノ酸又はその塩を高級アルコール硫酸エス
テル又はその塩と特定範囲で併用することにより、デキ
ストラナーゼの失活を防止してデキストラナーゼを口腔
用組成物中に安定に保持させることは知られている（特
開昭５６−１２３９１０号公報）が、具体的にＮ−パル
ミトイルザルコシン塩やＮ−ミリストイルザルコシン塩
とデキストラナーゼとを併用することは開示がない。デ
キストラナーゼにＮ−ラウロイルザルコシン塩を併用す
ることはこの公報に記載されているが、デキストラナー
ゼとＮ−ラウロイルザルコシン塩とを併用しても、後述
する実験例に示したように歯垢抑制に関して相乗効果は
発揮されないものであるが、Ｎ−パルミトイルザルコシ
ン塩やＮ−ミリストイルザルコシン塩をデキストラナー
ゼに併用した場合は顕著な相乗効果を示し、優れた歯垢
抑制効果を有するものであり、このことは本発明者等に
よる新知見である。 ゛以下１本発明につき更に詳
しく説明する。Conventionally, N-long chain acylamino acids or salts thereof, including N-lauroyl sarcosine salts, are used in combination with higher alcohol sulfate esters or salts thereof within a specific range to prevent the deactivation of dextranase. It is known that dextranase can be stably retained in oral compositions (JP-A-56-123910), but specifically, N-palmitoyl sarcosine salt or N-myristoyl sarcosine salt and dextranase There is no disclosure that it is used in combination with. This publication describes the use of N-lauroyl sarcosine salt in combination with dextranase, but even if dextranase and N-lauroyl sarcosine salt are used in combination, as shown in the experimental example described later, However, when N-palmitoyl sarcosine salt or N-myristoyl sarcosine salt is used in combination with dextranase, it shows a remarkable synergistic effect and has an excellent plaque inhibiting effect. This is a new finding by the present inventors.゛The present invention will be explained in more detail below.
本発明に係る口腔用組成物は、練歯磨、粉歯磨、液状歯
磨等の歯磨類、マウスウォッシュ、うがい用錠剤、歯肉
マツサージクリーム、チューインガム、トローチ剤など
として調製、適用されるもので、Ｎ−パルミトイルザル
コシン塩及び／又はＮ−ミリストイルザルコシン塩とデ
キストラナーゼとを歯垢形成抑制の有効成分として併用
したものである。The oral composition according to the present invention is prepared and applied as dentifrices such as toothpaste, powdered toothpaste, liquid toothpaste, mouthwash, gargling tablets, gingival massage cream, chewing gum, pastilles, etc. Palmitoyl sarcosine salt and/or N-myristoyl sarcosine salt and dextranase are used together as active ingredients for inhibiting dental plaque formation.
ここで、Ｎ−パルミトイルザルコシン塩又はＮ−ミリス
トイルザルコシン塩としては、それぞれナトリウム塩等
のアルカリ金属塩などが好適に使用される。Here, as the N-palmitoyl sarcosine salt or the N-myristoyl sarcosine salt, an alkali metal salt such as a sodium salt or the like is suitably used.
また、Ｎ−パルミトイルザルコシン塩及び／又はＮ−ミ
リストイルザルコシン塩の配合量は、組成物全体のｏ、
ｏｏｏｓ〜５％（１１１量％、以下同じ）、特に０．０
０１〜１．５％とすることが好ましい。なお、本発明に
おいては、このようにＮ−パルミトイルザルコシン塩及
び／又はＮ−ミリストイルザルコシン塩を使用し、これ
をデキストラナーゼと併用するもので、これにより顕著
な歯垢抑制の相乗効果を発揮するものであるが、他のＮ
−アシルザルコシン塩、即ちアシル基の炭素数が１２以
下のもの、例えばＮ−ラウロイルザルコシン塩はデキス
トラナーゼと併用しても歯垢抑制の相乗効果がなく、ま
たアシル基の炭素数が１８以上のものはその溶解性が劣
るので、いずれも本発明の目的を達成し得ない。In addition, the amount of N-palmitoyl sarcosine salt and/or N-myristoyl sarcosine salt is o,
ooos ~ 5% (111% by weight, same below), especially 0.0
It is preferable to set it as 01-1.5%. In addition, in the present invention, N-palmitoyl sarcosine salt and/or N-myristoyl sarcosine salt are used in combination with dextranase, thereby achieving a remarkable synergistic effect in inhibiting dental plaque. However, other N
- Acyl sarcosine salts, i.e. those in which the number of carbon atoms in the acyl group is 12 or less, such as N-lauroyl sarcosine salts, have no synergistic effect on inhibiting dental plaque when used in combination with dextranase, and those in which the number of carbon atoms in the acyl group is 18 or more Because of their poor solubility, none of them can achieve the purpose of the present invention.
また、デキストラナーゼはα−１，６−ゲルコジターゼ
活性を有するものであれば微生物起源の如何を問わず、
使用できる。その配合量は１例えば１００万単位／ｇの
デキストラナーゼを用いた場合、組成物全体のＯ，００
１〜２％、特に０．０１〜１％とすることが好ましい。In addition, dextranase can be used regardless of its microbial origin as long as it has α-1,6-gelcoditase activity.
Can be used. The blending amount is 1. For example, when using 1 million units/g of dextranase, the total amount of O,00
It is preferably 1 to 2%, particularly 0.01 to 1%.
本発明において、Ｎ−パルミトイルザルコシン塩及び／
又はＮ−ミリストイルザルコシン塩とデキストラナーゼ
との配合比は重量比で１：４００〜２００：１とするこ
とが好適で、この範囲で併用することにより両者の相乗
的な歯垢抑制作用が確実に発揮される。In the present invention, N-palmitoyl sarcosine salt and/or
Alternatively, the blending ratio of N-myristoyl sarcosine salt and dextranase is preferably 1:400 to 200:1 by weight, and by using them together within this range, the synergistic plaque inhibiting effect of both can be achieved. It will definitely be demonstrated.
本発明の口腔用組成物には、上記成分に加え、その種類
等に応じた適宜な成分が配合され得る。In addition to the above-mentioned components, the oral composition of the present invention may contain appropriate components depending on the type thereof.
例えば、練歯磨の場合であれば、第２リン酸カルシウム
、炭酸カルシウム、ピロリン酸カルシウム、不溶性メタ
リン酸ナトリウム、非晶質シリカ、結晶質シリカ、アル
ミノシリケート、酸化アルミニウム、水酸化アルミニウ
ム、レジン等の研磨剤、カルボキシメチルセルロース、
ヒドロキシエチルセルロース、アルギン酸塩、カラゲナ
ン、アラビアガム、ポリビニルアルコール等の粘結剤、
ポリエチレングリコール、ソルビトール、グリセリン、
プロピレングリコール等の粘稠剤、更に所望によりＮ−
パルミトイルザルコシン塩及びＮ−ミリストイルザルコ
シン塩以外の界面活性剤、例えばラウリル硫酸ナトリウ
ム、ドデシルベンゼンスルホン酸ナトリウム、水素添加
ココナツツ脂肪酸モノグリセリドモノ硫酸ナトリウム、
ラウリルスルホ酢酸ナトリウム、Ｎ−アシルグルタミン
酸塩、ショ糖脂肪酸エステル等、それにサッカリンナト
リウム、ステビオサイド、ネオヘスベリジルジヒドロカ
ルコン、グリチルリチン、ペリラルチン、ｐ−メトキシ
シンナミックアルデヒド、イソマルトース、パラチノー
ス、カップリングシュガー等の甘味剤、香料、防腐剤な
どの成分を水と混和し。For example, in the case of toothpaste, abrasives such as dicalcium phosphate, calcium carbonate, calcium pyrophosphate, insoluble sodium metaphosphate, amorphous silica, crystalline silica, aluminosilicate, aluminum oxide, aluminum hydroxide, resin, etc. carboxymethylcellulose,
Binder such as hydroxyethylcellulose, alginate, carrageenan, gum arabic, polyvinyl alcohol,
polyethylene glycol, sorbitol, glycerin,
Thickening agent such as propylene glycol, and optionally N-
Surfactants other than palmitoyl sarcosine salt and N-myristoyl sarcosine salt, such as sodium lauryl sulfate, sodium dodecylbenzenesulfonate, sodium hydrogenated coconut fatty acid monoglyceride monosulfate,
Sodium lauryl sulfoacetate, N-acylglutamate, sucrose fatty acid ester, etc., and sweetness such as saccharin sodium, stevioside, neohesberidyl dihydrochalcone, glycyrrhizin, perillartine, p-methoxycinnamic aldehyde, isomaltose, palatinose, coupling sugar, etc. Ingredients such as agents, fragrances, and preservatives are mixed with water.
常法に従って製造する。また、マウスウォッシュ等の口
腔洗浄剤その他においても、製品の性状に応じた成分が
適宜配合される。Manufactured according to conventional methods. In addition, in mouthwashes and other mouthwashes, ingredients are appropriately blended depending on the properties of the product.
なお１本発明口腔用組成物中には、クロルヘキシジン塩
、溶菌酵素、ムタナーゼ、ソルビン酸、アレキシジン、
ヒノキチオール、セチルピリジニウムクロライド、アル
キルグリシン、アルキルジアミノエチルグリシン塩、ア
ラントイン、ξ−アミノカプロン酸、トラネキサム酸、
アズレン、ビタミンＥ、水溶性第一もしくは第ニリン酸
塩、第四級アンモニウム化合物、塩化ナトリウムなどの
有効成分を更に配合することもできる。Note that the oral composition of the present invention contains chlorhexidine salt, lytic enzyme, mutanase, sorbic acid, alexidine,
Hinokitiol, cetylpyridinium chloride, alkylglycine, alkyldiaminoethylglycine salt, allantoin, ξ-aminocaproic acid, tranexamic acid,
Active ingredients such as azulene, vitamin E, water-soluble primary or diphosphoric acid salts, quaternary ammonium compounds, sodium chloride, etc. can also be added.
又皿Ｍ−羞米
本発明の１１腔用組成物は、Ｎ−バルミトイル及び／又
はＮ−ミリストイルザルコシン塩とデキストラナーゼと
を併用したことにより、これら成分の相乗作用で優れた
歯垢形成抑制効果を発揮し、従ってう触及び歯周病予防
効果の高いものである。In addition, the composition for cavity 11 of the present invention uses N-valmitoyl and/or N-myristoyl sarcosine salt and dextranase in combination, resulting in excellent plaque formation due to the synergistic effect of these components. It exhibits an inhibitory effect and is therefore highly effective in preventing caries and periodontal disease.
次に、実験例により本発明の効果を具体的に示す。Next, the effects of the present invention will be specifically illustrated by experimental examples.
デキストラナーゼとＮ−アシルザルコシン塩の併用によ
る歯垢形成抑制効果を下記方法により調べた。The effect of inhibiting dental plaque formation by the combination of dextranase and N-acylsarcosine salt was investigated by the following method.
去ｍ表
第１表に示す種類、添加量のサンプルを１％シヨ糖添加
フレーン・ハート・インフュージョン培地４ｍＱに溶解
し、これを試験管に入れると共に、この試験管にブレー
ン・ハート・インフュージョン培地によって予め３７℃
で１８時間嫌気培養したストレプトコッカス・ミュータ
ンス菌を接種後、試験管を３０度に傾けて１８時間嫌気
培養し、試験管壁に付着した菌量を測定する。対照とし
てサンプルを添加しない培地を用いて同様の実験を行な
い、その時の付着菌量（Ｘｏ）とサンプル液を用いたと
きの付着菌量（Ｘｓ）とから下記式（Ａ）により歯垢抑
制率を求める。結果を第１表に示す。Dissolve the samples of the type and amount shown in Table 1 in 4 mQ of Brain Heart Infusion Medium supplemented with 1% sucrose, place this in a test tube, and add Brain Heart Infusion to this test tube. Pre-incubate at 37°C with medium
After inoculating Streptococcus mutans bacteria that had been anaerobically cultured for 18 hours, the test tube was tilted at 30 degrees and cultured anaerobically for 18 hours, and the amount of bacteria attached to the test tube wall was measured. As a control, a similar experiment was conducted using a medium to which no sample was added, and the plaque inhibition rate was calculated using the following formula (A) from the amount of attached bacteria (Xo) at that time and the amount of attached bacteria (Xs) when using the sample solution. seek. The results are shown in Table 1.
歯垢抑制率（％）＝又ｌ二人”Ｘ１００・・・（Ａ）Ｘ
。Plaque suppression rate (%) = 2 people x 100... (A)
.
第１表
第１表の結果より、デキストラナーゼとＮ−バルミトイ
ル又はＮ−ミリストイルザルコシン塩とを併用した場合
、ストレプトコッカス・ミュータンスによる歯垢形成が
相乗的に抑制されることが認められた。これに対し、Ｎ
−ラウロイルザルコシン塩を用いた場合は、相乗効果を
殆ど示さないものであった。From the results in Table 1, it was confirmed that when dextranase and N-valmitoyl or N-myristoyl sarcosine salt were used together, plaque formation caused by Streptococcus mutans was inhibited synergistically. . On the other hand, N
- When lauroyl sarcosine salt was used, almost no synergistic effect was shown.
以下、実施例を示す。Examples are shown below.
〔実施例１〕練歯磨
第２リン酸カルシウム ５０％ソルビット
２０
カラゲナン １
サツカリンナトリウム ０．１ラウリル硫酸
ナトウリム １．２ラウリルジエタノールアミ
ド ０．５香 料
０．８デキストラナーゼ（８０万単位／ｇ）２
Ｎ−ミリストイルザルコシン
ナトリウム ０．５
クロルヘキシジングルコネート ０．０１計
１００％
〔実施例２〕練歯磨
水酸化アルミニウム ４４％ソルビット
３０
カラゲナン １
サツカリンナトリウム ０．１ラウリル硫酸
ナトウリム １．２ラウリルジエタノールアミ
ド ０．５香 料
０．８デキストラナーゼ（８０万単位／ｇ）２
Ｎ−ミリストイルザルコシン
ナトリウム ０．２５
Ｎ−パルミトイルザルコシン
ナトリウム ０．２５
モノフルオロリン酸ナトリウム ０．７６水
計 １００％
〔実施例３〕練歯磨
水酸化アルミニウム ４４％ソルビット
３０
カラゲナン １
サツカリンナトリウム ０．１ラウリル硫酸
ナトウリム １．２ラウリルジエタノールアミ
ド ０．５香 料
０．８デキストラナーゼ（８０万単位／ｇ）２
Ｎ−ミリストイルザルコシン
ナトリウム ０．５
セチルピリジニウムクロライド ０．０１モノフルオ
ロリン酸ナトリウム ０．７６鵞
計 １００％
〔実施例４〕粉歯磨
第２リン酸カルシウム ５０％炭酸カルシウム
２５
ソルビツト １０
ラウリル硫酸ナトウリム １
サツカリンナトリウム ０．１香 料
１デキストラナー
ゼ（１００万単位／ｇ）■Ｎ−ミリストイルザルコシン
ナトリウム ０．５
計 １００％
〔実施例５〕洗口剤
エチルアルコール ２０％α−オレフィン
スルホネート０．５
サツカリンナトリウム ０．１香 料
１ラウリルジエタ
ノールアミド ０．５デキストラナーゼ（５０万単
位／ｇ）３計 １００％
水で１０倍に希釈して使用する。[Example 1] Toothpaste dibasic calcium phosphate 50% sorbitol
20 Carrageenan 1 Saccharin Sodium 0.1 Sodium Lauryl Sulfate 1.2 Lauryl Diethanolamide 0.5 Flavor
0.8 dextranase (800,000 units/g)2
N-myristoyl sarcosine sodium 0.5 Chlorhexidine gluconate 0.01 total
100% [Example 2] Toothpaste aluminum hydroxide 44% sorbitol
30 Carrageenan 1 Saccharin sodium 0.1 Sodium lauryl sulfate 1.2 Lauryl diethanolamide 0.5 Flavor
0.8 dextranase (800,000 units/g)2
N-myristoyl sarcosine sodium 0.25 N-palmitoyl sarcosine sodium 0.25 Sodium monofluorophosphate 0.76 water total 100% [Example 3] Toothpaste aluminum hydroxide 44% sorbitol
30 Carrageenan 1 Saccharin sodium 0.1 Sodium lauryl sulfate 1.2 Lauryl diethanolamide 0.5 Flavor
0.8 dextranase (800,000 units/g)2
N-myristoyl sarcosine sodium 0.5 Cetylpyridinium chloride 0.01 Sodium monofluorophosphate 0.76 total 100% [Example 4] Powdered toothpaste dicalcium phosphate 50% calcium carbonate 25 Sorbit 10 Sodium lauryl sulfate 1 Satucharin Sodium 0.1 Flavor
1 Dextranase (1 million units/g) ■N-Myristoylsarcosine sodium 0.5 Total 100% [Example 5] Mouthwash Ethyl alcohol 20% α-olefin sulfonate 0.5 Satucalin sodium 0.1 fragrance fee
1 Lauryl diethanolamide 0.5 Dextranase (500,000 units/g) 3 total 100% Use by diluting 10 times with water.
〔実施例６〕 トローチ
アラビアゴム ６％ブドウ糖
３６香 料
１パラチノース
３６
デキストラナーゼ（１００万単位／ｇ）ＩＮ−ミリスト
イルザルコシン
ナトリウム ０．１
水 警
計 １００％
〔実施例７〕チユーインガム[Example 6] Lozenge gum arabic 6% glucose
36 fragrances
1 palatinose
36 Dextranase (1 million units/g) IN-myristoylsarcosine sodium 0.1 Water Keisei 100% [Example 7] Chewing gum
Claims (1)
シン塩及び／又はＮ−ミリストイルザルコシン塩とデキ
トスラナーゼとを併用してなることを特徴とする口腔用
組成物。 ２、Ｎ−パルミトイルザルコシン塩及び／又はＮ−ミリ
ストイルザルコシン塩の配合量が組成物全体の０．００
０５〜５重量％である特許請求の範囲第１項記載の口腔
用組成物。[Scope of Claims] 1. An oral composition comprising a combination of N-palmitoyl sarcosine salt and/or N-myristoyl sarcosine salt and dextosranase as active ingredients for inhibiting dental plaque. 2. The amount of N-palmitoyl sarcosine salt and/or N-myristoyl sarcosine salt is 0.00 of the entire composition.
The oral composition according to claim 1, wherein the amount is 0.05 to 5% by weight.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3623186A JPH0720854B2 (en) | 1986-02-20 | 1986-02-20 | Oral composition |
| DE19873705434 DE3705434A1 (en) | 1986-02-20 | 1987-02-20 | Dental care composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3623186A JPH0720854B2 (en) | 1986-02-20 | 1986-02-20 | Oral composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62195320A true JPS62195320A (en) | 1987-08-28 |
| JPH0720854B2 JPH0720854B2 (en) | 1995-03-08 |
Family
ID=12463995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3623186A Expired - Lifetime JPH0720854B2 (en) | 1986-02-20 | 1986-02-20 | Oral composition |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPH0720854B2 (en) |
| DE (1) | DE3705434A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0394470A1 (en) * | 1988-09-09 | 1990-10-31 | Sunstar Kabushiki Kaisha | Composition for oral cavity |
| JP2016199598A (en) * | 2011-12-26 | 2016-12-01 | ライオン株式会社 | Compositions for oral cavity |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0684294B2 (en) * | 1990-05-29 | 1994-10-26 | サンスター株式会社 | Oral composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA695572B (en) * | 1968-08-09 | 1971-03-31 | Colgate Palmolive Co | Oral preparation |
-
1986
- 1986-02-20 JP JP3623186A patent/JPH0720854B2/en not_active Expired - Lifetime
-
1987
- 1987-02-20 DE DE19873705434 patent/DE3705434A1/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0394470A1 (en) * | 1988-09-09 | 1990-10-31 | Sunstar Kabushiki Kaisha | Composition for oral cavity |
| JP2016199598A (en) * | 2011-12-26 | 2016-12-01 | ライオン株式会社 | Compositions for oral cavity |
| JP2017222720A (en) * | 2011-12-26 | 2017-12-21 | ライオン株式会社 | Composition for oral cavity |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0720854B2 (en) | 1995-03-08 |
| DE3705434A1 (en) | 1987-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2515637C (en) | Enzyme containing oral composition having enhanced stability | |
| US5110583A (en) | Peroxy acids composition for oral treatment | |
| US4990329A (en) | Composition for treating oral diseases | |
| RU2416391C1 (en) | Composition for oral cavity care | |
| GB2175805A (en) | Composition for treatment of oral diseases | |
| AU2013408771B2 (en) | Prebiotic oral care compositions containing an alkyl glycoside | |
| JPS63277612A (en) | Composition for oral cavity | |
| JPH10298048A (en) | Neutralizing agent for periodontopathic bacterial endotoxin, suppressant for adhesion of periodontopathic causative bacterium and composition for oral cavity | |
| JPS62195320A (en) | Composition for oral cavity | |
| JPH0925221A (en) | Fur-removing agent | |
| JPH06183940A (en) | Composition for oral cavity | |
| JPH0812541A (en) | Oral cavity composition | |
| JP2738092B2 (en) | Oral composition | |
| JP2001002542A (en) | Composition for oral cavity | |
| JPH06239723A (en) | Composition for oral cavity | |
| JPS5835484B2 (en) | Oral composition | |
| JP7424770B2 (en) | Gingival tissue destruction inhibitor | |
| JP2763824B2 (en) | Oral composition | |
| JPH07133222A (en) | Glucosyl transferase inhibitor | |
| JPH0826953A (en) | Composition for oral cavity | |
| JPH09110683A (en) | Antibacterial agent for oral cavity and composition for oral cavity | |
| JPH07165547A (en) | Composition for oral cavity | |
| JPH09110662A (en) | Halitosis eliminating agent and composition for oral cavity | |
| JPS6258324B2 (en) | ||
| JP2006151876A (en) | Composition for preventing periodontal disease |